Sino Biopharmaceutical (HKG:1177) said China's National Medical Products Administration gave approval for the marketing of the KRAS G12C inhibitor Garsorasib tablet, according to a Monday filing with the Hong Kong bourse.
Garsorasib, which is co-developed by the company, treats adult patients with KRAS G12C-mutated advanced non-small cell lung cancer who have received at least one systemic therapy, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.